GlassScriptPhysician profile
Kara E Cockfield
NPI 1427083914
$1,751.80
in general payments reported to CMS, 2019-2025
21 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $161 · 2021: $287 · 2022: $363 · 2023: $211 · 2024: $225 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.12 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Aspira Women'S Health INC | $222.75 | 2021-2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $162.79 | 2021-2025 | |
| Biogen, INC. | $136.19 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $105.57 | 2019-2025 | Veozah |
| Gynesonics, INC. | $82.79 | 2021 | |
| Pfizer INC. | $81.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $68.83 | 2019-2021 | |
| Hologic Sales and Service, LLC | $66.30 | 2023-2024 | Myosure Tissue Removal Device, Aptima, Novasure |
| Minerva Surgical, INC | $63.04 | 2025 | |
| Allergan, INC. | $59.85 | 2019-2022 | |
| Daiichi Sankyo INC. | $59.36 | 2019-2022 | |
| Channel Medsystems, INC. | $50.35 | 2022-2023 | |
| Organon LLC | $34.64 | 2022-2024 | |
| Baxter Healthcare | $29.44 | 2023 | Tisseel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.83 | 2023 | Myfembree |
| Axonics, INC. | $20.36 | 2021 | |
| Medtronic, INC. | $18.68 | 2024 | Truclear |
| Alexion Pharmaceuticals, INC. | $18.24 | 2020 | |
| Coopersurgical, INC. | $16.06 | 2024 | Paragard T 380a |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Cockfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.